ICBII UPDATE: NEW PATENT ACCELERATES TREATING NEURO-DEGENERATIVE DISEASES

ICBII UPDATE: THE ROAD TO THE CURE

A REAL-TIME SCIENCE REPORT

NEW PATENT ACCELERATES TREATING 

NEURO-DEGENERATIVE DISEASES

LA JOLLA, Calif., April 15, 2020 / PRNewswire — Innovative California Biosciences International, Inc., (“ICBII”), announced on April 15th the approval of its patent for Blood-Brain Barrier (BBB) Permeable Peptide Composition. Further validating the unique capability of ICBII’s SMART molecules (SMs) in overcoming the age-old BBB problem in treating diseases of the brain, this is ICBII’s 6th US and international patent. 

It is estimated that 98% of all drugs cannot cross the BBB. The ones that do cross the BBB only provide short-term symptomatic relief without altering disease progression.   

SMs are designed to enter the brain, target specific disease-causing proteins, and trigger immune response to eradicate an intended target. Unlike classical mouse monoclonal antibodies used by pharmaceutical companies in their failed clinical trials, SMs do not target insulin and transferrin receptors on the BBB, which mitigates the potential of systemic toxicity.  

Unique attributes of SMs technology, including the ability to inhibit pathogenic enzymes, brings ICBII closer to its goal of enabling precise diagnoses and disease altering therapies of diseases like Alzheimer’s, Parkinson’s, Multiple System Atrophy (MSA), and Glioblastoma. With its sixth approved patent, five pending approval and several patents in the pipeline, ICBII continues to build a strong portfolio of proprietary intellectual property to protect its SMART molecules platform technology and to launch new commercial disease altering products for central nervous system (CNS) diseases.

SMART* Molecules (SMs) are novel miniaturized antibody mimics with efficient BBB uptake. (SMART* is an acronym that stands for Specific Molecular Architecture for Recognition and Therapy). This technology has been tested and verified by third parties in animal models of Alzheimer’s and Parkinson’s diseases. Among its array of SMs, ICBII has developed a SM for α-synuclein, a key Parkinson’s disease target, which, when administered intravenously, allows quantitation of aberrant α-synuclein in the brain of mice and halts its expression in a dose dependent manner. 

“This latest patent approval is a major advancement in moving the SMs technology platform forward towards treating Parkinson’s, Alzheimer’s, Glioblastoma, MSA, and other CNS diseases,” stated Ram Bhatt PhD, Founder of ICBII. Applicable to any new CNS targets, SMs can potentially change the paradigm and cure many human diseases, including infections and cancers that have not been successfully treated so far.

Optimization of Parkinson’s Drug

In collaboration with Gen-Script of New Jersey, ICBII is developing eight new analogs of its alpha-Syn-SM to choose one that has optimal therapeutic efficacy, BBB permeability, and none to minimal toxicity. The lockdown due to coronavirus has significantly hindered scientific progress.